ERBB2 and gastroesophageal junction adenocarcinoma: On August 13, 2024, based on findings from the primary analysis of DESTINY-Gastric06, trastuzumab deruxtecan (T-DXd) was granted conditional approval in China for adult patients with locally advanced or metastatic HER2+ gastric or GEJ adenocarcinoma who have received two or more prior treatment regimens.